ライフサイエンスコーパス: lymphocytic lymphoma

1 el17p chronic lymphocytic leukaemia or small lymphocytic lymphoma.

2 eated chronic lymphocytic leukaemia or small lymphocytic lymphoma.

3 t-naive and relapsed/refractory CLL or small lymphocytic lymphoma.

4 ocytic leukaemia and two patients with small lymphocytic lymphoma.

5 nts with relapsed or refractory CLL or small lymphocytic lymphoma.

6 eption of chronic lymphocytic leukemia/small lymphocytic lymphoma.

7 0.21) for chronic lymphocytic leukemia/small lymphocytic lymphoma.

8 nd B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma.

9 0.4, 0.3; p trend = 0.03) with risk of small lymphocytic lymphoma.

10 with chronic lymphocytic leukaemia or small lymphocytic lymphoma.

11 -cell and chronic lymphocytic leukemia/small lymphocytic lymphomas.

12 cell lymphomas, such as follicular and small lymphocytic lymphomas.

13 f its potential target genes, B-cell chronic lymphocytic /lymphoma 11B (BCL11B) was predicted.

14 odgkin's lymphomas, including cases of small lymphocytic lymphoma (18 cases), marginal zone lymphoma

15 protective gene product BCL2 (B cell chronic lymphocytic lymphoma 2) in the SGZ.

16 ded follicular lymphoma (72 patients), small lymphocytic lymphoma (28), marginal-zone lymphoma (15),

17 All patients had follicular or small cell lymphocytic lymphoma after relapse from a prior response

18 zinc finger domains (TRAF2DN) develop small lymphocytic lymphoma and chronic lymphocytic leukemia wi

19 Most of the published data concern chronic lymphocytic lymphoma and diffuse large B-cell lymphoma,

20 n between chronic lymphocytic leukemia/small lymphocytic lymphoma and rs735665 (combined P = 4.24 x 1

21 ma (137 diffuse, 58 follicular, and 32 small lymphocytic lymphomas) and 63 cases of B-CLL were identi

22 group C (chronic lymphocytic leukemia/small lymphocytic lymphoma, and other indolent lymphomas).

23 ymphomas (6 marginal zone lymphomas, 7 small lymphocytic lymphomas, and 13 follicular lymphomas, grad

24 The large lymphoid cells in small lymphocytic lymphoma are also rich in hsp89, but not hsp

25 splantation was found to have stage IV small lymphocytic lymphoma at the time of transplantation.

26 one lymphoma (MZL), MALT lymphoma or B-small lymphocytic lymphoma (B-SLL) cell lines or patient sampl

27 homa (Case 1), follicular lymphoma and small lymphocytic lymphoma (Case 2), and mantle cell lymphoma

28 phoma and chronic lymphocytic leukemia/small lymphocytic lymphoma (Case 3).

29 isk of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL).

30 91 after chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and 111 after other NHL s

31 (FL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) but not for other NHL sub

32 rates of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) declined 2.1% per year.

33 is, RR of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) was 1.66 (95% CI, 1.08-2.

34 d that chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) was the principal NHL sub

35 exist for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

36 quency in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

37 , but not chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; HR, 0.84; 95% CI, 0.31 to

38 106), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; N = 133).

39 , such as chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; n = 15), mantle cell lymp

40 mphomas, 2 follicular lymphomas, 4 CLL/small lymphocytic lymphomas (CLL/SLLs), and 1 low-grade NHL no

41 cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (diffusely positive in 33 cases), w

42 For patients with small lymphocytic lymphoma, dosing began at 10 mg/day to avoid

43 including chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, and mantle ce

44 patients with relapsed/refractory CLL/small lymphocytic lymphoma harboring ATM deletions/mutations;

45 ntrast to follicle center lymphoma and small lymphocytic lymphoma; however, pRB expression does not a

46 Interfollicular small lymphocytic lymphoma (I-SLL) has not been well character

47 promoting chronic lymphocytic leukemia/small lymphocytic lymphoma in mice, possibly by specifically e

48 ts with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk

49 atic chronic lymphocytic leukaemia, or small lymphocytic lymphoma is encouraging, and merits further

50 CD20, expressed on greater than 90% of B-lymphocytic lymphomas, is an attractive target for antib

51 B cells (chronic lymphocytic leukemia/small lymphocytic lymphomas, mantle cell lymphomas, and precur

52 One patient with transformed small lymphocytic lymphoma met criteria for complete response,

53 (n = 3), mantle cell lymphoma (n = 2), small lymphocytic lymphoma (n = 2), and myeloid leukemia (n =

54 (n = 4), lymphoplasmacytic (n = 1), or small lymphocytic lymphoma (n = 3); and CLL (n = 11), were enr

55 0), marginal zone lymphoma (n=30), and small lymphocytic lymphoma (n=30) were enrolled from June 30,

56 Low-grade, small lymphocytic lymphomas of the mucosa-associated lymphoid

57 None of the B-cell small lymphocytic lymphomas or mantle cell lymphomas expressed

58 chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma patients who are followed for a med

59 vation in chronic lymphocytic leukemia/small lymphocytic lymphoma, plasma cell myeloma, mantle cell l

60 el17p chronic lymphocytic leukaemia or small lymphocytic lymphoma received oral ibrutinib 420 mg once

61 with chronic lymphocytic leukaemia or small lymphocytic lymphoma relapse after initial therapy.

62 1.96) and chronic lymphocytic leukemia/small lymphocytic lymphoma (relative risk = 1.93, 95% confiden

63 matic chronic lymphocytic leukaemia or small lymphocytic lymphoma requiring therapy.

64 rade 1 or 2, and 22% (four of 18) with small lymphocytic lymphoma responded to therapy.

65 0.78) and chronic lymphocytic leukemia/small lymphocytic lymphoma (RR, 0.46; 95% CI, 0.21-1.01), and

66 efractory chronic lymphocytic leukemia/small lymphocytic lymphoma (RR-CLL/SLL), irrespective of risk

67 Of 30 evaluable patients with small lymphocytic lymphoma, seven (23%) had a complete respons

68 Small lymphocytic lymphoma showed minimal TG staining, with ot

69 ded eight chronic lymphocytic leukemia/small lymphocytic lymphomas, six mantle cell lymphomas, seven

70 (MCL), immunocytoma (IMC), and small B-cell lymphocytic lymphoma (SLL) are B-cell malignancies that

71 Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are currently considered the

72 icular lymphoma, 11 had MCL, three had small lymphocytic lymphoma (SLL) or chronic lymphocytic leukem

73 characterized and its relationship to small lymphocytic lymphoma (SLL) or chronic lymphocytic leukem

74 effect was most pronounced for the CLL/small lymphocytic lymphoma (SLL) subtype (OR: 1.0; 3.2 [0.7-15

75 ith chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) that was maintained at 24 hou

76 nts with relapsed or refractory CLL or small lymphocytic lymphoma (SLL) to assess safety, pharmacokin

77 ith chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who presented at The Universi

78 ith chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response

79 non-Hodgkin's lymphoma (NHL), such as small lymphocytic lymphoma (SLL), and many other cancers.

80 Patients with CLL/small lymphocytic lymphoma (SLL), prolymphocytic leukemia, or

81 as compared with that of patients with small lymphocytic lymphoma (SLL)/B-cell chronic lymphocytic le

82 en reported to have little activity in small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia

83 omas (FL), three transformed FLs, four small lymphocytic lymphomas (SLL), two Waldenstrom's macroglob

84 tumors (10.5%), which included 1 of 45 small lymphocytic lymphomas (SLLs), 2 of 38 follicular small c

85 sk of the chronic lymphocytic leukemia/small lymphocytic lymphoma subtype among women only (253 cases

86 For chronic lymphocytic leukemia/small lymphocytic lymphoma, suggestive associations were noted

87 e associations of body mass index with small lymphocytic lymphoma versus B-CLL may be a chance findin

88 ational Workshop on CLL guidelines) or small lymphocytic lymphoma were eligible for this phase 1b, do

89 e CPP32 immunopositive, whereas 3 of 3 small lymphocytic lymphomas were CPP32 negative, suggesting th

90 el17p chronic lymphocytic leukaemia or small lymphocytic lymphoma who received at least one dose of s

91 ctive chronic lymphocytic leukaemia or small lymphocytic lymphoma with measurable lymph node disease